Premium
Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center
Author(s) -
Han Jin,
Bhat Shubha,
Gowhari Michel,
Gordeuk Victor R.,
Saraf Santosh L.
Publication year - 2016
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.1834
Subject(s) - medicine , pharmacy , clinical pharmacy , pharmacist , pediatrics , emergency medicine , family medicine
Ambulatory care clinical pharmacy services have expanded beyond primary care settings, but literature supporting the benefits of clinical pharmacy involvement with patients who have rare diseases such as sickle cell disease ( SCD ) is lacking. Hydroxyurea is the only agent approved by the U.S. Food and Drug Administration for the treatment of SCD ; full benefit in controlling pain episodes and other complications is achieved through monitored escalation to a maximum tolerated dose. The primary objective of this analysis was to evaluate the impact of a newly implemented clinical pharmacy service on the management of patients with SCD . We performed a retrospective cross‐sectional analysis of 385 adults with SCD who received care between January 1, 2014, and December 31, 2014, at a single Sickle Cell Outpatient Center that implemented a clinical pharmacy service in August 2013. Data were collected on hydroxyurea dose escalation, immunization completion rates, and health maintenance metrics (screening for nephropathy with microalbuminuria testing, retinopathy with annual retinal examinations, and pulmonary hypertension with echocardiography). The impact of the clinical pharmacy service on quality measurements was evaluated by using univariate and multivariate analyses. The number of pharmacist encounters, defined as a clinic visit when a clinical pharmacist interacted with a patient as documented in the medical records, was associated with an improved hydroxyurea dose escalation rate (odds ratio [ OR ] 1.48, 95% confidence interval [ CI ] 1.07–2.05, p=0.02). Immunization rates for the 23‐valent pneumococcal polysaccharide vaccine, the 13‐valent pneumococcal conjugate vaccine, and influenza vaccine were 66%, 47%, and 62%, respectively. The number of pharmacist encounters was associated with improved immunization completion rates ( OR 1.38, 95% CI 1.17–1.62, p<0.001). Improved screening for microalbuminuria ( OR 2.14, 95% CI 1.60–2.86, p<0.001) and sickle cell retinopathy ( OR 1.16, 95% CI 1.00–1.35, p=0.05) were also associated with the number of pharmacist encounters. A new clinical pharmacy service implemented in managing a rare disease, SCD , was associated with an improved hydroxyurea dose escalation rate, immunization completion rates, and health maintenance metrics.